Onyvax Limited Release: Phase IIb Clinical Trial Of Onyvax-P In Early Stage Prostate Cancer Initiated In United States  
9/28/2007 11:29:37 AM

London, UK, 26 September 2007: Onyvax Ltd, the biotechnology company developing novel cancer therapies, announced today that a Phase IIb clinical trial with Onyvax-P, designed to stimulate the immune system to fight prostate cancer, is now underway at the National Cancer Institute, Bethesda, Maryland.